Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT

This is a multi-center, randomized, double-blinded, placebo controlled trial.

开始日期2022-06-16

申办/合作机构

Priothera SAS

NCT01830010

/ Completed临床1期

A Two-part, Single- and Two Arm Randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy (in Part 2 Only) of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies

Two part study to evaluate the safety, tolerability, pharmacokinetics, and efficacy (in Part 2 only) of KRP203 in patients undergoing allogeneic hemopoietic stem cell transplant for hematological malignancies

开始日期2013-06-28

申办/合作机构

Novartis Pharmaceuticals Corp.

NCT01294774

/ Completed临床2期

A Multi-center, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy and Tolerability of KRP203 in Patients With Active Subacute Cutaneous Lupus Erythematosus

This study will assess the safety and efficacy of KRP203 in clinically active subacute cutaneous lupus erythematosus patients, who have demonstrated inadequate response to standard treatment, such as antimalarials.

开始日期2011-02-01

申办/合作机构

Novartis Pharmaceuticals Corp.

100 项与 Mocravimod hydrochloride 相关的临床结果

登录后查看更多信息

100 项与 Mocravimod hydrochloride 相关的转化医学

登录后查看更多信息

100 项与 Mocravimod hydrochloride 相关的专利（医药）

登录后查看更多信息

项与 Mocravimod hydrochloride 相关的文献（医药）

2026-08-01·LEUKEMIA

Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors

Article

作者: Mustafa Ali, Moaath K ; Baer, Maria R ; Traer, Elie ; Liu, Yuchen ; Wang, Yin ; Chatterjee, Aditi ; Bailey, Christopher M ; Smith, Catherine C ; Small, Donald ; Silvestri, Giovannino

FLT3 inhibitor efficacy in AML with FLT3-ITD is short-lived, frequently due to new mutations, most commonly in NRAS. Sphingosine kinase 1 (SPHK1), which phosphorylates sphingosine to generate sphingosine-1-phosphate (S1P), is upregulated and localized to the plasma membrane in RAS-mutated cells. We studied S1P and FLT3 co-targeting to overcome FLT3 inhibitor resistance in NRAS-mutated FLT3-ITD AML cells. NRAS-mutated FLT3-ITD AML cell lines and patient blasts were treated with FLT3 inhibitors and/or S1P receptor (S1PR) modulators. FLT3 inhibitor sensitivity was assessed by immunoblotting, cytotoxicity, apoptosis and colony formation. Co-treatment was also assessed in vivo in an orthotopic mouse model. Downstream RAS and SPHK1 effectors were measured by immunoblotting and qRT-PCR. The S1PR modulators fingolimod (FTY720) and mocravimod (KRP-203) resensitized FLT3-ITD-expressing MOLM-14 and MV4-11 human AML cells with G12D, G12S, Q61K or Q61H, but not G12C, and patient blasts with G13D, G13V or G12D NRAS mutations to FLT3 inhibitors. Moreover, FTY720 co-treatment resensitized G12D NRAS-mutated M14(R)701 cells to gilteritinib in vivo. Co-treatment inactivated ERK, transcriptionally downregulated SPHK1, and inactivated downstream AKT, p70 S6K and BAD, with inactivation abrogated by constitutive SPHK1 expression. The clinically applicable S1PR modulators fingolimod and mocravimod resensitize NRAS-mutated FLT3-ITD AML cells to FLT3 inhibitors, supporting potential clinical efficacy.

2026-05-01·BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Polypharmacologic phosphoinositide modulation by FTY720 triggers endomembrane trafficking collapse and metabolic starvation in cancer cells

Article

作者: Simeonov, Anton ; Wakimoto, Hiroaki ; Hirota, Yoshihisa ; Takeuchi, Koh ; Ito, Doshun ; Sumita, Kazutaka ; Kofuji, Satoshi ; Tabata, Sho ; Senda, Toshiya ; Takahashi, Yasufumi ; Kanoh, Hirotaka ; Sasaki, Mika ; Nakatsu, Fubito ; Davis, Mindy I ; Hirayama, Akiyoshi ; Shen, Min ; Soga, Tomoyoshi ; Sasaki, Atsuo T ; Ikeda, Yoshiki

Phosphoinositides coordinate membrane trafficking and bioenergetic homeostasis, and many tumors rely on elevated phosphoinositide flux to sustain growth. Therapeutic development has largely pursued single-phosphoinositide kinase inhibition, whereas polypharmacologic strategies that perturb the broader network remain underexplored. FTY720 (fingolimod), a clinically approved sphingosine-1-phosphate receptor modulator, shows anti-tumor activity at micromolar concentrations, but its non-canonical mechanisms remain incompletely defined. Building on our work with the structurally related compound KRP203, we show that high-dose FTY720 produces isozyme-divergent modulation across phosphoinositide kinases and biases PIKFYVE activity toward phosphatidylinositol, a pattern we term ASURA (Asymmetric Simultaneous Uncoupling of Related Activities). FTY720 induces vacuolization and endomembrane remodeling in cancer cells, and suppresses macropinocytic ruffling as demonstrated by tracer uptake and scanning ion conductance microscopy analyses. Quantitative metabolomics revealed depletion of intracellular amino acids and ribonucleoside triphosphates, coupled with reduced glycolysis. Concurrently, FTY720 induced extensive rewiring of the hexosamine pathway, nitrogen metabolism, and tricarboxylic acid (TCA)-cycle anaplerosis, along with redox signatures indicating oxidative stress despite a nutrient-replete medium. The metabolites depleted by FTY720 showed extensive, directionally concordant overlap with those depleted by PTEN induction. Patient-derived glioblastoma (GBM) neurospheres were sensitive to FTY720, and co-treatment with a PI3Kα-selective inhibitor augmented growth suppression in U87MG cells. Together, these data support a model in which ASURA-dose FTY720 disrupts phosphoinositide-regulated trafficking and nutrient access, imposing intracellular nutrient stress that culminates in tumor-cell death.

2026-02-01·Clinical Pharmacology in Drug Development

Clinical assessment of mocravimod as a victim of drug–drug interactions via CYP3A4 metabolism and transporters

Article

Abstract:

Mocravimod, a novel immunomodulator targeting sphingosine‐1‐phosphate receptor (S1PR), is being developed as a maintenance treatment for patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Preclinical data suggested that cytochrome (CYP) 3A4 is the primary enzyme involved in mocravimod metabolism. In vitro data showed that both mocravimod and its active metabolite mocravimod‐phosphate are substrates for breast cancer resistance protein (BCRP) and P‐glycoprotein (P‐gp) but not for organic‐anion‐transporting polypeptides (OATP1B1 and OATP1B3). As mocravimod is co‐administered with CYP3A4 inhibitors such as azoles or cyclosporin, the potential for drug–drug interactions (DDIs) was evaluated. In addition, the effect of BCRP, P‐gp, and OATP via cyclosporin co‐administration was assessed. Two open‐label, two‐period, fixed‐sequence studies were conducted in healthy subjects to evaluate the DDI potential of mocravimod and 1) itraconazole, a dual CYP3A4/P‐gP inhibitor, or 2) cyclosporin, a moderate inhibitor of CYP3A4 and P‐gp, BCRP, OATP1B1, and OATP1B3. Safety and tolerability were also monitored. The PK of mocravimod and mocravimod‐phosphate were bioequivalent with or without co‐administration of multiple doses of itraconazole and a moderate interaction is observed when co‐administered with cyclosporin. The most commonly‐reported treatment‐emergent adverse events were bradycardia and decreased lymphocyte count, which are expected side effects for S1PR modulators.

项与 Mocravimod hydrochloride 相关的新闻（医药）

2026-09-03

·BioSpace

Priothera Appoints Experienced Biotech Executive, Dr Nigel Clark, as Chief Business Officer to Lead Strategic Partnering for Mocravimod

Priothera is the only company in advanced clinical development with a potential maintenance treatment for patients with acute myeloid leukaemia undergoing allogeneic hematopoietic cell transplantation Saint-Louis, France and Dublin, Ireland – 3 September 2026 : Priothera, a late-stage clinical biopharmaceutical company developing mocravimod, an orally applied sphingosine 1-phosphate (S1P) receptor modulator for haematological malignancies, announces the appointment of Nigel Clark, PhD, as Chief Business Officer (CBO). Dr Clark brings more than 25 years of commercial and strategic leadership experience across the biotechnology and pharmaceutical industries, with particular expertise in business and corporate development, licensing, M&A and transaction execution. In his new role, he will work closely with Priothera’s leadership team to maximise the commercial potential of mocravimod and lead efforts to secure strategic partnership opportunities with global pharmaceutical and biotechnology companies. Mocravimod is currently being evaluated in a pivotal international Phase 3 study (MO-TRANS) in patients with Acute Myeloid Leukaemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT). This unique oral therapy is designed to increase the graft-versus-leukaemia (GvL) effect with the potential to improve the relapse and survival outcomes for patients following transplant. Priothera is the only company in advanced clinical development with a potential maintenance treatment for AML patients undergoing allo-HCT. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Florent Gros, Co-Founder and CEO of Priothera , commented, “Welcoming Nigel to our leadership team comes at an important stage for Priothera as we advance mocravimod through pivotal Phase 3 development. His extensive track record in business development and executing major strategic transactions will be invaluable as we engage with potential partners to maximise the value of mocravimod and, ultimately, its potential to reach patients who need new treatment options.” Prior to joining Priothera, Dr Clark served as CBO of Nucleome Therapeutics. Previously, he was Senior Vice President of Business Development and a member of the executive team at Kymab, which was acquired by Sanofi in 2021 for $1.1 billion upfront and up to $350 million in milestones. Earlier in his career, he served as CBO of Syntaxin, which was acquired by Ipsen, and held senior business development roles at Vernalis, Ribotargets and British Biotech. Over the course of his career, Dr Clark has negotiated and executed more than 20 major transactions. Dr Nigel Clark, Chief Business Officer of Priothera, said, “ Mocravimod is a particularly compelling late-stage opportunity, with a differentiated mechanism and the potential to address the significant challenge of relapse following allo-HCT in AML. With the programme advancing through pivotal Phase 3 development, I am excited to join Priothera at this important stage and look forward to engaging with prospective partners to help realise mocravimod’s potential for patients .” xxx ezstandalone.cmd.push(function () { ezstandalone.showAds(132); }); About mocravimod Mocravimod is a synthetic S1P receptor modulator being developed for the adjunctive and maintenance treatment of AML to enhance the curative potential of allo-HCT. Mocravimod’s unique mechanism of action increases the graft-versus-leukaemia (GvL) effect, critical for eliminating cancer. This novel treatment approach – mocravimod being the only S1P receptor modulator in development to treat blood cancers – tackles a high unmet medical need and aims to improve treatment outcomes and patients’ quality of life. About Priothera Priothera is a late-stage biopharma company pioneering the development of mocravimod, a potential new standard of care in hematologic cancers, in addition to cellular therapies such as allo-HCT and CAR-T cell therapies. Mocravimod is being developed as an adjunctive and maintenance therapy for haematological malignancies requiring allogeneic hematopoietic cell transplantation (allo-HCT), focusing initially on acute myeloid leukaemia (AML). Mocravimod is currently the only treatment with the potential to increase the graft’s anticancer effect against leukaemia (Graft-versus-Leukaemia, or GvL), thereby enhancing the curative potential of allo-HCT. Founded in 2020, Priothera operates in France, with headquarters in Dublin. The company is led by a highly experienced management team with deep expertise in haematology, oncology, immunology and cell-based therapies. Priothera is backed by leading international life sciences investors. For more information please visit or follow Priothera on LinkedIn ezstandalone.cmd.push(function () { ezstandalone.showAds(133); }); Contacts Priothera Florent Gros, CEO E: info@priothera.com Nigel Clark, CBO E: nigel.clark@priothera.com MEDiSTRAVA Consulting Sylvie Berrebi, Sandi Greenwood, Frazer Hall E: priothera@medistrava.com T: +44 (0) 203 928 6900

2025-06-27

·GlobeNewswire-Health Care

Priothera Secures €1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program

Priothera Secures €1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program Funding to support MOCART, a clinical programme evaluating mocravimod added to standard CAR-T cell therapy 24 June 2025– Priothera, a late-stage biopharma company pioneering the development of mocravimod, a novel oral sphingosine 1 phosphate (S1P) receptor modulator, to treat hematologic malignancies, today announced that it has been awarded nearly €1.7 million in non-dilutive funding through the i-Nov innovation competition. Part of the France 2030 initiative, i-Nov is a flagship French government program operated by Bpifrance to support breakthrough innovation from high-potential French companies across strategic sectors. The funding will support Priothera’s clinical programme to evaluate whether adding mocravimod to commercial CAR-T cell therapies could improve patient outcomes. CAR-T cell therapies represent a novel and promising modality for the treatment of hematological malignancies. They have demonstrated the potential for remarkable clinical responses and durable disease control in patients with acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma and multiple myeloma. However, their use is still associated with significant challenges, as 40-60% of patients treated with CAR-T cells experience high-grade toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), a form of severe neurological toxicity. Mocravimod is a novel, oral S1P receptor modulator with a unique dual mechanism of action that has the potential to enhance the effectiveness of CAR-T cell therapy by: Reducing the incidence and severity of CRS and ICANS, and Improving response rates and durability of treatment “We are honoured to receive this i-Nov funding from Bpifrance, which underscores the innovation and therapeutic potential of mocravimod beyond allo-HCT,” said Florent Gros, Co-Founder and CEO of Priothera. “With its unique immunomodulatory properties, mocravimod is well-positioned to become a key component in the next generation of cell therapy regimens. The MOCART trial represents an exciting expansion of our clinical development into CAR-T therapy, building on our deep expertise in allo-HCT and momentum from our ongoing global Phase 3 MO-TRANS trial in acute myeloid leukemia.” Priothera continues to advance mocravimod in the MO-TRANS global Phase 3 study for patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT). The company remains focused on unlocking the full therapeutic potential of S1P receptor modulation across multiple settings in blood cancers. Mocravimod (KRP203) is a synthetic S1P receptor modulator being developed for the adjunctive and maintenance treatment of AML to enhance the curative potential of allo-HCT. Mocravimod’s dual mechanism of action preserves the graft-versus-leukemia (GvL) effect, critical for eliminating cancer cells while reducing the risk of graft-versus-host disease (GvHD), a major complication following allo-HCT. This novel treatment approach – mocravimod being the only S1P receptor modulator in development to treat blood cancers – tackles a high unmet medical need and aims to improve treatment outcomes and patients’ quality of life. Priothera is a late-stage biopharma company pioneering the development of mocravimod, a potential new standard of care in hematologic cancers, in addition to cellular therapies such as hematopoietic cell transplantation and CAR-T cell therapies. Mocravimod is being developed as an adjunctive and maintenance therapy for hematological malignancies requiring allogeneic hematopoietic cell transplant (allo-HCT), focusing initially on acute myeloid leukemia (AML). Mocravimod is currently the only treatment with the potential to reduce transplant side effects of graft-versus-host disease (GvHD) without compromising the graft’s anticancer effect against leukemia (Graft-versus-Leukemia, or GvL), thereby enhancing the curative potential of allo-HCT. Founded in 2020, Priothera operates in France, with headquarters in Dublin. The company is led by a highly experienced management team with deep expertise in hematology, oncology, immunology and cell-based therapies. Priothera is backed by leading international life sciences investors, including Fountain Healthcare Partners, abrdn, EarlyBird Venture Capital, BEI and Bpifrance Grand Est. The content above comes from the network. if any infringement, please contact us to modify.

免疫疗法细胞疗法

2025-06-03

·GlobeNewswire-Health Care

Priothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen

Highly experienced clinical development executive joins Priothera Board as mocravimod progresses through global Phase 3 trial as adjunctive and maintenance treatment in AML patients undergoing allo-HCT Saint-Louis, France and Dublin, Ireland – 3rd June 2025– Priothera Ltd., a late-stage biopharma company pioneering the development of mocravimod, a novel oral sphingosine 1 phosphate (S1P) receptor modulator, to treat hematologic malignancies, today announced the appointment of Dr. Hans Menssen, MD, PhD, BBA, to its Board of Directors. Dr. Menssen most recently served as Senior Global Program Clinical Head at Novartis Oncology, where he led clinical programs across acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), multiple myeloma, chronic myeloid leukemia (CML), myelofibrosis, acute and chronic GvHD, and B-cell malignancies, with a focus on registration-stage development. Over his career, in addition to Novartis, he has held senior roles at Bayer Schering Pharma and Philogen SpA, with a track record of supporting oncology innovation across modalities including small molecules, antibodies, and cell therapies. “Hans brings deep strategic insight in hematology, clinical development, and regulatory science,” said Florent Gros, Co-Founder and CEO of Priothera. “His experience across global drug development programs and his understanding of what it takes to bring innovative therapies to patients will make him a valuable voice on our Board as we progress the global Phase 3 MO-TRANS study of mocravimod in AML patients undergoing allo-HCT. We are very pleased to welcome him to the Board.” A board-certified hematologist and oncologist, Dr. Menssen also holds academic appointments at Charité – University Medicine Berlin in his capacity as assistant professor (Priv-Doz. Dr. med), where he continues to teach and supervise medical research. He has contributed to numerous clinical and translational research efforts throughout his career. He earned his medical degree from the University of Cologne, completed postdoctoral research at the Wistar Institute at the University of Pennsylvania, and holds a Bachelor of Business Administration in health economics from GSBA Zurich in partnership with SUNY (State University of New York). “I am very pleased to join Priothera’s Board at such a key point in its evolution,” said Dr. Hans Menssen. “Mocravimod represents a promising and differentiated approach to improving outcomes in AML patients undergoing allo-HCT, and I look forward to supporting the team in advancing this important program.” Priothera’s Board of Directors is composed of: Dr. Manus Rogan (Chair) – Managing Partner, Fountain Healthcare PartnersMr. Florent Gros - CEODr. Marten Steen – Managing Partner, Healthcap VenturesDr. Henry Skinner – CEO, AMR Action FundMr. Lionel Carnot – Partner, Earlybird HealthDr. Hans Menssen – former Senior Global Program Clinical Head, Novartis Oncology *** About mocravimodMocravimod (KRP203) is a synthetic S1P receptor modulator being developed for the adjunctive treatment of AML to enhance the curative potential of allo-HCT. Mocravimod’s dual mechanism of action preserves the graft-versus-leukemia (GvL) effect, critical for eliminating cancer cells while reducing the risk of graft-versus-host disease (GvHD), a major complication following allo-HCT. This novel treatment approach – mocravimod being the only S1P receptor modulator in development to treat blood cancers – tackles a high unmet medical need and aims to improve patients’ quality of life. About PriotheraPriothera is a late-stage biopharma company pioneering the development of mocravimod, a potential new standard of care in hematologic cancers, in combination with cellular therapies such as hematopoietic cell transplantation and CAR-T cell therapies. Mocravimod is being developed as an adjunctive and maintenance therapy for hematological malignancies, focusing initially on acute myeloid leukemia (AML), in combination with allogeneic hematopoietic cell transplant (allo-HCT). Mocravimod is currently the only treatment with the potential to reduce transplant side effects of graft-versus-host disease (GvHD) without compromising the graft’s anticancer effect against leukemia (Graft-versus-Leukemia, or GvL), thereby enhancing the curative potential of allo-HCT. Founded in 2020, Priothera operates in France, with headquarters in Dublin. The company is led by a highly experienced management team with deep expertise in hematology, oncology, immunology and cell-based therapies. Priothera is backed by leading international life sciences investors, including Fountain Healthcare Partners, abrdn, EarlyBird Venture Capital, BEI and Bpifrance Grand Est. For more information please visit www.priothera.com or follow Priothera on LinkedIn www.linkedin.com/company/priothera/ Contacts PriotheraFlorent Gros, CEOE: info@priothera.com MEDiSTRAVA ConsultingSylvie Berrebi, Frazer HallE: priothera@medistrava.comT: +44 (0) 203 928 6900

高管变更细胞疗法临床3期免疫疗法

100 项与 Mocravimod hydrochloride 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12771 D12772	-	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
成人急性髓性白血病	临床3期	美国	Priothera SAS	2022-06-16
成人急性髓性白血病	临床3期	日本	Priothera SAS	2022-06-16
成人急性髓性白血病	临床3期	阿根廷	Priothera SAS	2022-06-16
成人急性髓性白血病	临床3期	巴西	Priothera SAS	2022-06-16
成人急性髓性白血病	临床3期	法国	Priothera SAS	2022-06-16
成人急性髓性白血病	临床3期	德国	Priothera SAS	2022-06-16
成人急性髓性白血病	临床3期	以色列	Priothera SAS	2022-06-16
成人急性髓性白血病	临床3期	意大利	Priothera SAS	2022-06-16
成人急性髓性白血病	临床3期	波兰	Priothera SAS	2022-06-16
成人急性髓性白血病	临床3期	罗马尼亚	Priothera SAS	2022-06-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05429632 (MO-TRANS, ASH2025)	临床3期	急性髓性白血病维持	366	Mocravimod 1mg	觸醖簾糧淵窪製鹹獵獵(繭淵窪範衊顧鹹窪顧糧) = 簾糧顧範醖繭餘夢艱廠齋壓齋製鬱醖鏇廠繭艱 (鏇壓願築窪齋淵鹹範範 )	积极	2025-12-06
				Mocravimod 3mg	憲簾觸艱襯蓋壓憲構選(艱襯遞夢範顧鑰願艱範) = 夢鹹鏇觸繭觸壓艱齋夢繭壓鑰艱餘淵範鹹簾壓 (製膚艱網鬱夢鬱顧廠網 ) 更多
NCT01830010 (PRNewswire) 人工标引	临床1期	造血干细胞移植	-	mocravimod	顧簾憲觸願憲願獵衊築(繭築齋獵餘構願網蓋鑰) = Mocravimod is safe and well-tolerated in allogeneic hematopoietic cell transplantation (HCT) patients 築餘襯鹹襯淵鏇範廠鬱 (齋鹽願築淵網獵簾餘壓 )	积极	2022-11-14
Tandem Meetings ASTCT and CIBMTR2022	临床1期	血液肿瘤	-	3mg KRP203+CsA/MTX	衊網醖選顧廠簾鏇獵襯(醖窪壓糧繭窪構遞鑰憲) = 夢醖願夢膚艱餘積襯齋積淵鹽簾顧齋網遞壓鏇 (憲艱繭願壓鬱壓衊構網 ) 更多	积极	2022-03-01
				1mg KRP203+CsA/MTX	衊網醖選顧廠簾鏇獵襯(醖窪壓糧繭窪構遞鑰憲) = 獵艱觸範範願餘廠簾艱積淵鹽簾顧齋網遞壓鏇 (憲艱繭願壓鬱壓衊構網 ) 更多
NCT01830010 (P229, EBMT2019)	临床1期	移植物抗宿主病	23	KRP203 3 mg/day + tacrolimus/MTX	願構蓋糧製顧顧鑰遞壓(繭蓋製衊壓鏇顧獵衊鹹) = 齋製積衊網顧憲艱網壓鹽築醖襯範淵鏇壓壓範 (齋鹽構餘觸鏇窪鹽構鹽 ) 更多	积极	2019-03-24
				KRP203 1 mg/day + CsA/MTX	願構蓋糧製顧顧鑰遞壓(繭蓋製衊壓鏇顧獵衊鹹) = 鹽憲製餘製鏇製鬱艱鹽鹽築醖襯範淵鏇壓壓範 (齋鹽構餘觸鏇窪鹽構鹽 ) 更多
ECCO2016	临床2期	溃疡性结肠炎	30	KRP203 1.2 mg	鹽壓醖顧膚蓋憲夢艱衊(醖觸範鑰艱選餘願簾艱) = 憲範壓襯獵鏇願窪繭鏇顧繭憲餘網衊夢顧製窪 (獵簾觸鏇構衊艱廠鬱憲 ) 更多	积极	2016-02-12
				Placebo	鹽蓋顧顧願淵糧鏇鏇積(築壓鑰艱選製襯鑰衊衊) = 製觸構網鬱製窪繭醖構簾構膚蓋製觸餘觸顧選 (夢糧觸淵築窪繭壓壓糧 )